NDAINTRAVENOUSPOWDERPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
RECARBRIO (imipenem anhydrous, cilastatin, and relebactam anhydrous) by Merck & Co. is dipeptidase inhibitors [moa]. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RECARBRIO is a fixed-dose combination of imipenem (carbapenem antibiotic), cilastatin (renal dehydropeptidase inhibitor), and relebactam (beta-lactamase inhibitor) administered intravenously. It is indicated for serious bacterial infections caused by gram-negative organisms with resistance mechanisms. The triple combination enhances imipenem's spectrum and overcomes certain beta-lactamase-mediated resistance.
$0.001BPart D
Peak6.9 years to LOEProduct is in peak lifecycle phase with modest Part D adoption, suggesting stable but niche market positioning with limited sales force expansion.
Mechanism of Action
Dipeptidase Inhibitors
Pharmacologic Class:
Renal Dehydropeptidase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RECARBRIO shows zero linked job postings, indicating limited dedicated headcount or career visibility within Merck's public hiring. Roles likely embedded within broader infectious disease or hospital infection control teams rather than standalone product units.
Company
Worked on RECARBRIO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.